Semantic Coherence: Ridgeback Biotherapeutics – Signal Evidence & AI Readability

[IMG: Girl benefiting from treatment options]

Ridgeback Biotherapeutics develops potential medications to treat infectious diseases that have limited or no treatment options, like Ebola and COVID-19.

[H2] Our Difference: We commit resources and expertise for poorly-understood diseases.
Tens of millions of people worldwide suffer every year from known and emerging infectious diseases that have few therapeutic options, both in the developing world and more recently due to global pandemic illness.
At Ridgeback, we commit resources and expertise for undefined and poorly understood diseases early in the pharmaceutical development cycle, at a time generally when few stakeholders are prepared to make the necessary commitments.

[H2] Featured Press

Press Release / Business Wire 10.20.2021
Ridgeback Biotherapeutics Responds to 13th Ebola Outbreak in Democratic Republic of Congo

Media / CNBC, Squawk on the Street 10.01.2021
Ridgeback Biotherapeutics co-founders, Wayne and Wendy Holman, on how a pill can tackle Covid-19

Media / The Wall Street Journal 12.20.2021
Behind a New Pill to Treat Covid: Wayne and Wendy Holman and a Hunch that led to its creation

+ More

[H1] 404 Not Found

cloudflare

[H1] Press

All
EBANGA™
Lagevrio (molnupiravir)

Publication / JMIR Public Health and Surveillance 09.18.2025
Effectiveness of Antivirals Nirmatrelvir-Ritonavir and Molnupiravir in Viral Sepsis: Retrospective Cohort Study

Press Release / PR Newswire 09.12.2025
The National Institute of Biomedical Research and Ridgeback Biotherapeutics Respond to 16th Ebola Outbreak in the Democratic Republic of Congo

Publication / PharmacoEconomics Open 04.23.2025
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in High-Risk Older Adults in Japan

Publication / Microorganisms 03.15.2025
Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study)

Publication / BMC Pregnancy and Childbirth 02.26.2025
Maternal and fetal survival following Ebola, HIV and Malaria co-infection in the first trimester of gestation in resource-limited setting in Democratic Republic of Congo

Publication / Center for Infectious Disease Research and Policy 11.20.2024
Antiviral COVID-19 drug molnupiravir tied to large drop in deaths in older patients

Publication / Italian Journal of Medicine 06.03.2024
Prevention is better than healing. Clinical and economic implications of oral antiviral agents in COVID-19: a prospective study

Publication / The Journal of Infection in Developing Countries 05.30.2024
Molnupiravir’s real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study

Publication / Infectious Diseases and Therapy 05.14.2024
Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review

Publication / Journal of Clinical Medicine 04.16.2024
Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic

Publication / Clinical and Translational Science 02.08.2024
Molnupiravir: Mechanism of action, clinical, and translational science

Publication / Microbiology Spectrum 02.01.2024
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)

Publication / Infectious Diseases and Therapy 01.17.2024
Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan

Publication / Antimicrobial Agents and Chemotherapy 12.04.2023
Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance

Publication / Clinical Infectious Diseases 12.01.2023
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial

Publication / Infectious Diseases and Therapy 11.23.2023
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Publication / Frontiers In Pharmacology 11.15.2023
Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial

Press Release / HHS 10.27.2023
Letter to COVID-19 therapeutics manufacturers, distributors, pharmacies and the health care payer community

Publication / CPT: Pharmacometrics & Systems Pharmacology 10.05.2023
Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals

Press Release / HHS – ASPR 09.29.2023
Lagevrio Prepares for Transition to Commercial Distribution

Publication / JAMA Network Open 09.21.2023
Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections

Publication / Journal of Infection 09.08.2023
Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial

Publication / Clinical Therapeutics 08.17.2023
Hospitalization Among Patients Treated With Molnupiravir: A Retrospective Study of Administrative Data

Publication / Epidemiologia 08.10.2023
Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel

Publication / Clinical and Translational Science 08.01.2023
Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants

Publication / Cureus 05.05.2023
Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A MetaAnalysis

Publication / Clinical Pharmacology & Therapeutics 04.05.2023
Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes

Publication / Infectious Diseases and Therapy 03.16.2023
Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan

Publication / Frontiers in Pharmacology 03.08.2023
Ebanga™: The most recent FDA-approved drug for treating Ebola

Publication / Drug Design, Development and Therapy 01.19.2023
The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19

Publication / Infection 01.17.2023
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial

Media / Global Times 01.15.2023
1st batch of Molnupiravir available at mainland hospitals as new option for COVID-19 patients

Media / The Mighty 790 KFGO 01.10.2023
Ridgeback Biotherapeutics and Merck’s COVID treatment expected to launch in China on Friday

Media / Clinical Trials Arena 12.22.2022
Excellence Awards 2022 – Winners Announced!

Publication / Clinical and Experimental Medicine 12.05.2022
Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic

Media / Chemical & Engineering News 12.01.2022
ACS celebrates its 2022 Heroes of Chemistry including Ridgeback Biotherapeutics

Publication / Cureus 11.14.2022
Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India

Press Release / Open PR 11.07.2022
COVID-19 Oral Medicine Market Trends, Analysis and Forecast till 2028 | Key Players Novartis AG, Merck & Co, Atea Pharmaceuticals, Ridgeback Biotherapeutics, Pfizer Inc

Media / SHINE 11.05.2022
Biopharmaceutical ‘writing our future’ at CIIE

Publication / The Lancet Infectious Diseases 10.19.2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Press Release / Bloomberg 10.06.2022
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)

Publication / Clinical and Translational Science 08.31.2022
A phase I, randomized, placebo-controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID-19

Publication / Clinical Infectious Diseases 08.24.2022
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Media / Reuters 08.19.2022
WHO recommends use of two antibody drugs against Ebola

Press Release / GlobeNewswire 07.07.2022
Wendy Holman’s Ridgeback Biotherapeutics and Emergent BioSolutions Enter Into Agreement for Ebanga™ Treatment for Ebola

Publication / PharmacoEconomics 07.02.2022
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US

Press Release / Business Wire 06.07.2022
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study

Publication / Annals of Internal Medicine 06.07.2022
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19

Press Release / Business Wire 04.01.2022
Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo

Publication / The New England Journal of Medicine 03.23.2022
Antibody Use during an Outbreak of Ebola Virus Disease in the Democratic Republic of Congo, 2020

Media / Bloomberg 03.02.2022
Ridgeback Biotherapeutics and Merck’s Covid Antiviral Gets WHO Backing for High-Risk Patients

Media / New York Times 02.20.2022
A Covid pill developed with the help of Ridgeback Biotherapeutics reduces the risk of hospitalization

Publication / Drugs 02.20.2022
Molnupiravir: First Approval

Press Release / Business Wire 02.08.2022
Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States

Press Release / Business Wire 01.28.2022
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies

Media / Reuters 01.21.2022
Dozens of firms to make cheap version of Merck COVID pill for poorer nations

Publication / Science Translational Medicine 01.19.2022
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

Press Release / Merck 01.18.2022
Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine

Press Release / Business Wire 12.24.2021
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan

Press Release / Business Wire 12.23.2021
Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19

Press Release / Business Wire 12.22.2021
Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir

Media / The Wall Street Journal 12.20.2021
Behind a New Pill to Treat Covid: Wayne and Wendy Holman and a Hunch that led to its creation

Press Release / Business Wire 12.16.2021
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine

Publication / The New England Journal of Medicine 12.16.2021
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Publication / NEJM Evidence 12.16.2021
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults

Media / Fortune 12.01.2021
Antiviral pill developed in partnership between Merck and Wendy Holman’s, Ridgeback Biotherapeutics, are likely to maintain efficacy against the Omicron COVID variant— even if vaccines don’t

Press Release / Business Wire 11.30.2021
Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults

Press Release / Business Wire 11.26.2021
Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Press Release / Business Wire 11.17.2021
Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting

Publication / Journal of Antimicrobial Chemotherapy 11.12.2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Press Release / Business Wire 11.10.2021
Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval

Press Release / Business Wire 11.09.2021
Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults

Media / The Washington Post 11.04.2021
Britain is the first country to authorize the antiviral pill jointly developed by Merck and Ridgeback Biotherapeutics to treat coronavirus

Media / Wall Street Journal 11.04.2021
Merck Covid-19 Pill Cleared for Use in U.K., Its First Authorization

Press Release / Business Wire 11.04.2021
Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World

Media / New York Times 10.27.2021
Licensing deal will allow poor countries to manufacture and sell cheaply the Covid-19 pill, developed by Merck in partnership with Wendy Holman’s Ridgeback Biotherapeutics

Press Release / Business Wire 10.27.2021
The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries

Press Release / Business Wire 10.25.2021
Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults

Media / New York Times 10.20.2021
Gates Foundation pledge to help poor countries by supplying them with Covid pill that was developed in record time by Ridgeback Biotherapeutics and Merck

Media / Reuters 10.20.2021
Gates Foundation allots $120 mln for poor nations to get COVID-19 drug

Press Release / Business Wire 10.20.2021
Ridgeback Biotherapeutics Responds to 13th Ebola Outbreak in Democratic Republic of Congo

Press Release / Business Wire 10.11.2021
Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults

Media / CNBC 10.06.2021
Dr. Gottlieb sees Covid’s ‘pandemic phase’ ending when antiviral pills,

[H1] Privacy Policy and Terms of Use

This Privacy Policy describes Our policies and procedures on the collection, use and disclosure of Your information when You use the Service and tells You about Your privacy rights and how the law protects You.
We use Your Personal data to provide and improve the Service. By using the Service, You agree to the collection and use of information in accordance with this Privacy Policy.
[H2] Interpretation and Definitions
[H3] Interpretation
The words of which the initial letter is capitalized have meanings defined under the following conditions. The following definitions shall have the same meaning regardless of whether they appear in singular or in plural.
[H3] Definitions
For the purposes of this Privacy Policy:
Account means a unique account created for You to access our Service or parts of our Service.Company (referred to as either “the Company”, “We”, “Us” or “Our” in this Agreement) refers to Ridgeback Biotherapeutics, 3480 Main Highway, Unit 402, Miami, FL 33133.Cookies are small files that are placed on Your computer, mobile device or any other device by a website, containing the details of Your browsing history on that website among its many uses.Country refers to the United StatesDevice means any device that can access the Service such as a computer, a cellphone or a digital tablet.Personal Data is any information that relates to an identified or identifiable individual.Service refers to the Website.Service Provider means any natural or legal person who processes the data on behalf of the Company. It refers to third-party companies or individuals employed by the Company to facilitate the Service, to provide the Service on behalf of the Company, to perform services related to the Service or to assist the Company in analyzing how the Service is used.Usage Data refers to data collected automatically, either generated by the use of the Service or from the Service infrastructure itself (for example, the duration of a page visit).Website refers to Ridgeback Biotherapeutics, accessible from ridgebackbio.comYou means the individual accessing or using the Service, or the company, or other legal entity on behalf of which such individual is accessing or using the Service, as applicable.
[H2] Collecting and Using Your Personal Data
[H3] Types of Data Collected
[H4] Personal Data
While using Our Service, We may ask You to provide Us with certain personally identifiable information that can be used to contact or identify You. Personally identifiable information may include, but is not limited to:
Email AddressFirst Name and Last NamePhone NumberAddress, State, Province, ZIP/Postal code, CityUsage DataMedical InformationPayment Information
[H4] Usage Data
Usage Data is collected automatically when using the Service.
Usage Data may include information such as Your Device’s Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Service that You visit, the time and date of Your visit, the time spent on those pages, unique device identifiers and other diagnostic data.
When You access the Service by or through a mobile device, We may collect certain information automatically, including, but not limited to, the type of mobile device You use, Your mobile device unique ID, the IP address of Your mobile device, Your mobile operating system, the type of mobile Internet browser You use, unique device identifiers and other diagnostic data.
We may also collect information that Your browser sends whenever You visit our Service or when You access the Service by or through a mobile device.
[H4] Tracking Technologies and Cookies
We use Cookies and similar tracking technologies to track the activity on Our Service and store certain information. Tracking technologies used are beacons, tags, and scripts to collect and track information and to improve and analyze Our Service. The technologies We use may include:
Cookies or Browser Cookies. A cookie is a small file placed on Your Device. You can instruct Your browser to refuse all Cookies or to indicate when a Cookie is being sent. However, if You do not accept Cookies, You may not be able to use some parts of our Service. Unless you have adjusted Your browser setting so that it will refuse Cookies, our Service may use Cookies.Flash Cookies. Certain features of our Service may use local stored objects (or Flash Cookies) to collect and store information about Your preferences or Your activity on our Service. Flash Cookies are not managed by the same browser settings as those used for Browser Cookies. For more information on how You can delete Flash Cookies, please read “Where can I change the settings for disabling, or deleting local shared objects?” available at https://helpx.adobe.com/flash-player/kb/disable-local-shared-objects-flash.html#main_Where_can_I_change_the_settings_for_disabling__or_deleting_local_shared_objects_Web Beacons. Certain sections of our Service and our emails may contain small electronic files known as web beacons (also referred to as clear gifs, pixel tags, and single-pixel gifs) that permit the Company, for example, to count users who have visited those pages or opened an email and for other related website statistics (for example, recording the popularity of a certain section and verifying system and server integrity).
Cookies can be “Persistent” or “Session” Cookies. Persistent Cookies remain on Your personal computer or mobile device when You go offline, while Session Cookies are deleted as soon as You close Your web browser. Learn more about cookies: What Are Cookies?.
We use both Session and Persistent Cookies for the purposes set out below:
Necessary / Essential Cookies
Type: Session Cookies
Administered by: Us
Purpose: These Cookies are essential to provide You with services available through the Website and to enable You to use some of its features. They help to authenticate users and prevent fraudulent use of user accounts. Without these Cookies, the services that You have asked for cannot be provided, and We only use these Cookies to provide You with those services.
Cookies Policy / Notice Acceptance Cookies
Type: Persistent Cookies
Administered by: Us
Purpose: These Cookies identify if users have accepted the use of cookies on the Website.
Functionality Cookies
Type: Persistent Cookies
Administered by: Us
Purpose: These Cookies allow us to remember choices You make when You use the Website, such as remembering your login details or language preference. The purpose of these Cookies is to provide You with a more personal experience and to avoid You having to re-enter your preferences every time You use the Website.
[H3] Use of Your Personal Data
The Company may use Personal Data for the following purposes:
To provide and maintain our Service, including to monitor the usage of our Service.To manage Your Account and Your registration as a user of the Service. The Personal Data You provide can give You access to different functionalities of the Service that are available to You as a registered user.For the performance of a contract: We may use your information in the development, compliance and undertaking of the purchase contract for the products, items or services You have purchased or of any other contract with Us through the Service.To contact You by email, telephone calls, SMS, or other equivalent forms of electronic communication, such as a mobile application’s push notifications regarding updates or informative communications related to the functionalities, products or contracted services, including the security updates, when necessary or reasonable for their implementation.To provide You with news, special offers and general information about other goods, services and events which we offer that are similar to those that you have already purchased or enquired about unless You have opted not to receive such information.To manage Your requests: To attend and manage Your requests to Us.For business transfers: We may use Your information to evaluate or conduct a merger, divestiture, restructuring, reorganization, dissolution, or other sale or transfer of some or all of Our assets, whether as a going concern or as part of bankruptcy, liquidation, or similar proceeding, in which Personal Data held by Us about our Service users is among the assets transferred.For other purposes: We may use Your information for other purposes, such as data analysis, identifying usage trends, research, determining the effectiveness of our promotional campaigns and to evaluate and improve our Service, products, services, marketing and your experience.
We may share Your personal information in the following situations:
With Service Providers: We may share Your personal information with Service Providers to monitor and analyze the use of our Service and to contact You.For business transfers: We may share or transfer Your personal information in connection with, or during negotiations of, any merger, sale of Company assets, financing, or acquisition of all or a portion of Our business to another company.With Affiliates: We may share Your information with Our affiliates, in which case we will require those affiliates to honor this Privacy Policy. Affiliates include Our parent company and any other subsidiaries, joint venture partners or other companies that We control or that are under common control with Us.With business partners: We may share Your information with Our business partners to offer You certain products, services or promotions.With Your consent: We may disclose Your personal information for any other purpose with Your consent.
[H3] Retention of Your Personal Data
The Company will retain Your Personal Data only for as long as is necessary for the purposes set out in this Privacy Policy. We will retain and use Your Personal Data to the extent necessary to comply with our legal obligations (for example, if we are required to retain your data to comply with applicable laws), resolve disputes, and enforce our legal agreements and policies.
The Company will also retain Usage Data for internal analysis purposes. Usage Data is generally retained for a shorter period of time, except when this data is used to strengthen the security or to improve the functionality of Our Service, or We are legally obligated to retain this data for longer time periods.
[H3] Transfer of Your Personal Data
Your information, including Personal Data, is processed at the Company’s operating offices and in any other places where the parties involved in the processing are located. It means that this information may be transferred to — and maintained on — computers located outside of Your state, province, country or other governmental jurisdiction where the data protection laws may differ than those from Your jurisdiction.
Your consent to this Privacy Policy followed by Your submission of such information represents Your agreement to that transfer.
The Company will take all steps reasonably necessary to ensure that Your data is treated securely and in accordance with this Privacy Policy and no transfer of Your Personal Data will take place to an organization or a country unless there are adequate controls in place including the security of Your data and other personal information.
[H3] Disclosure of Your Personal Data
[H4] Business Transactions
If the Company is involved in a merger, acquisition or asset sale, Your Personal Data may be transferred. We will provide notice before Your Personal Data is transferred and becomes subject to a different Privacy Policy.
[H4] Law enforcement
Under certain circumstances, the Company may be required to disclose Your Personal Data if required to do so by law or in response to valid requests by public authorities (e.g. a court or a government agency).
[H4] Other legal requirements
The Company may disclose Your Personal Data in the good faith belief that such action is necessary to:
Comply with a legal obligationProtect and defend the rights or property of the CompanyPrevent or investigate possible wrongdoing in connection with the ServiceProtect the personal safety of Users of the Service or the publicProtect against legal liability
[H3] Security of Your Personal Data
The security of Your Personal Data is important to Us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While We strive to use commercially acceptable means to protect Your Personal Data, We cannot guarantee its absolute security.
[H2] Children’s Privacy
Our Service does not address anyone under the age of 13. We do not knowingly collect personally identifiable information from anyone under the age of 13. If You are a parent or guardian and You are aware that Your child has provided Us with Personal Data, please contact Us. If We become aware that We have collected Personal Data from anyone under the age of 13 without verification of parental consent, We take steps to remove that information from Our servers.
[H2] Links to Other Websites
Our Service may contain links to other websites, products, or services that are not owned or operated by Us. If You click on a third party link, You will be directed to that third party’s site. We have no control over and assume no responsibility for the content, privacy policies or practices of any third party sites or services. We strongly advise You to review the Privacy Policy of every site You visit.
[H2] Geographic Restriction
Our Service is hosted in the United States and intended for individuals located within the United States of America. We make no representations that our Service is appropriate or available for use in any location outside of the United States. If you are a resident of another country, or are accessing the Service from outside of the United States, please note that you are transferring your data to the United States which does not have the same data protection laws as the European Union and other regions.
[H2] Your Choices
Your use of our Service is voluntary. You may decline to share certain information with us, in which case we may not be able to provide you with some or all of the features and functionality of our Service. You can also contact us at [email protected] to request access to review, change, correct or delete any information that you have provided to us. We may not accommodate a request to change information if we believe the change would violate any law or legal requirement or cause the information to be incorrect. You may also ask us to deactivate your account. Although we can remove your information from our active databases, some or all information from deactivated accounts will remain in our inactive database for compliance with legal, regulatory, and other requirements. Information that has been de-identified, anonymized, aggregated, published, and/or shared with third parties prior to an account deactivation request may not be retrievable or traced back for destruction, deletion, o